Table 5.
Long-term cost-effectiveness outcomes from the supporting analyses based on the NMA
| Health outcomes | Semaglutide 0.5 mg | Semaglutide 1 mg | Exenatide ER | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Lixisenatide |
|---|---|---|---|---|---|---|
| Discounted life expectancy (years) | 14.16 (0.21) | 14.26 (0.19) | 14.07 (0.21) | 14.04 (0.20) | 14.12 (0.20) | 13.98 (0.19) |
| Discounted quality-adjusted life expectancy (QALYs) | 8.94 (0.13) | 9.14 (0.12) | 8.75 (0.13) | 8.73 (0.12) | 8.80 (0.12) | 8.55 (0.12) |
| Discounted direct costs (DKK) | 431,248 (10,024) | 416,147 (9771) | 428,031 (10,687) | 429,730 (9883) | 462,218 (10,721) | 448,210 (11,094) |
| ICER for semaglutide 0.5 mg (DKK per QALY gained) | – | – | 17,024 | 7390 | Semaglutide 0.5 mg dominant | Semaglutide 0.5 mg dominant |
| ICER for semaglutide 1 mg (DKK per QALY gained) | – | – | Semaglutide 1 mg dominant | Semaglutide 1 mg dominant | Semaglutide 1 mg dominant | Semaglutide 1 mg dominant |
Values are means (standard deviations)
DKK 2017 Danish kroner, ER extended-release, ICER incremental cost-effectiveness ratio, QALYs quality-adjusted life years